The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer has designed and validated a custom small gene panel to interrogate genes relevant in the clinical management of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Any patient with a new diagnosis of CLL/SLL or with relapsed/refractory CLL/SLL requiring treatment qualifies for testing, in addition to the current FISH panel.
This Next Generation Sequencing (NGS) panel includes the sequence analysis of selected coding regions of the following genes: TP53, BCL2, PLCG2, BTK, SF3B1, NOTCH1, BIRC3 and MYD88. This NGS panel does not detect copy number or structural variants, so FISH analysis is still necessary to identify copy number changes of 17p (TP53), 11q (ATM), 13q and chromosome 12. Further details of the methods and the genes and regions covered can be found here.
CLL NGS Panel can be ordered using the CGL Lymphoid Requisition found on our Requisitions page. Additional information can be found in our memo.